US FDA Generic Drug Office Director Uhl Announces Retirement
Uhl, who shepherded OGD into the user fee era, will retire in February.
You may also be interested in...
US FDA's Woodcock tells the Pink Sheet that goals include eliminating duplication through creation of one safety review process.
Workforce report to Congress, mandated by 21st Century Cures Act, details FDA's plans for implementing its new authorities provided by the law.
Long-planned OND 'modernization' to better match workflow, allow more time with stakeholders includes proposed restructuring that would boost number of offices overseeing review operations (adding four for a total of nine) and drug review divisions (adding 11 for a total of 30).